Abbvie

AbbVie closed with a modest 1.4% gain at 256.92, reaching an intraday peak of 258.26 during active trading. Near-term catalysts include clarification of the Phase 3 EPCORE DLBCL-1 trial evaluating Epcoritamab (Duobody-CD3xCD20, developed with Genmab) in relapsed/refractory diffuse large B-cell lymphoma, and EU approval of Allergan Aesthetics' Boey treatment for frown lines. Market sentiment also reflects ongoing analysis of the company's $10.9B Apogee acquisition's impact on dividend policy. On the earnings front, Q1 2026 revenue reached $15.0B, up 12.4% year-over-year, yet net profit declined 46.3% to $685M, with net margin compressing from Q4's 10.9% to 4.6%, signaling significant profitability pressure. The stock trades near its 52-week high of $261.64 (1.8% below), up 12.0% year-to-date and trading well above its 60-day moving average of $227.65. Valuation appears stretched, with a P/E ratio of 126.3.

AbbVie fell approximately 1.1% during regular trading to $253.30, pressured by divergent Q1 earnings results and profit-taking after its recent rally. While first-quarter revenue rose 12.43% year-over-year to $15 billion, diluted earnings per share collapsed 46.25% to $0.387 and net income tumbled 46.32% to $685 million, with net margin compressing sharply from 10.93% in the prior quarter to just 4.63%. The company is progressing its $10.9 billion acquisition of Apogee, expanding its aesthetics and regenerative medicine offerings but introducing uncertainty around future dividend sustainability. Trading at year-to-date gains of 10.46% and sitting only 3.19% below its 52-week high of $261.64 (set July 2nd), the stock commands a lofty 124.5x PE multiple, suggesting substantial earnings recovery has been priced into the valuation—a thesis now facing headwinds from disappointing Q1 profit results.

AbbVie advanced 1.07% to $256.10 today, hitting fresh near-term highs, buoyed by positive analyst sentiment and steady demand for core immunology products. BMO Capital Markets reiterated a constructive stance on the company, highlighting the continued growth trajectory of key drugs like Skyrizi and Rinvoq; the firm also completed a $10.9 billion Apogee acquisition to strengthen its aesthetics portfolio. Intraday momentum pushed the stock to $257.04, trading just 2.12% below the 52-week high of $261.635 and above both its 20- and 60-day moving averages, with year-to-date gains of 11.68%. However, Q1 earnings revealed a 46.25% year-over-year decline in EPS to $0.387, with net margin compressing from 10.93% in Q4 to 4.63% in Q1, while the stock's elevated PE multiple of 125.86x suggests markets are pricing in meaningful profit recovery.

AbbVie closed at $253.38 today, down 0.44% in a pullback reflecting profit-taking after multiple catalysts. Pre-market trading pushed the stock as high as $255.78, but regular-session momentum peaked at $255.86 ET around 09:50 before shifting lower, with intraday lows near $252.68 and post-market sliding further to $252.08 before a modest bounce. BMO Capital Markets lifted its price target last week on strong immunology drug momentum, the EU approved Allergan's Boey for frown lines, and the company announced a $10.9 billion acquisition of Apogee to reinforce dividend capacity — catalysts that sparked a 3.32% rebound on July 16th following a seven-session selloff. However, Q1 earnings expose underlying profitability challenges: while revenue expanded 12.4% year-over-year to $15.02 billion, EPS plunged 46% to $0.39 as margins compressed sharply — net profit margin fell to 4.6% from 10.9% in the prior quarter. The stock trades roughly 3% below its July 2 peak of $261.64, yet remains up 10.5% year-to-date and sits well above its 60-day moving average, demonstrating medium-term support despite earnings headwinds.

AbbVie shares closed near flat at $254.49 after intraday pullback, as profit-taking pressure weighed following yesterday's 3.32% surge. Intraday high reached $260.725 before retreating, with premarket strength from $252.675 to $256.93 unable to sustain into the session. Year-to-date gains stand at +10.98%, with stock trading near 52-week highs, just 2.73% below the peak of $261.635. On the institutional side, BMO Capital Markets upgraded its price target on July 8th, highlighting continued strength in immunology franchises, while Bank of America issued a positive outlook. However, Q1 2026 earnings show significant sequential deterioration, with EPS declining 46% to $0.387 from Q4's $1.018, and net profit falling from $1.806 billion to $685 million, alongside margin compression from 10.93% to 4.63%, which could limit further upside momentum.